Neumora Therapeutics, Inc. Stock News

The FDA places a clinical hold on Neumora's (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.

Neumora Therapeutics (NASDAQ: NMRA ) stock is falling on Monday after the clinical-stage biopharmaceutical company announced a clinical hold on a Phase 1 trial of NMRA-266. The Food and Drug Administ

Neumora Therapeutics (NMRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that

Many investors are familiar with the idea that there are many reasons why insiders sell shares, but there's only one reason they buy. Insider buying indicates a belief that a company's stock is underv

WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that

The IPO market in 2023 has been anything but hot. After a record-breaking year in 2021, the appetite for new listings has cooled down significantly, first in 2022 and continuing into the current year.

Amgen Inc.'s disclosure Wednesday of a large stake in Neumora Therapeutics Inc. indicates that the value of its investment in the biopharmaceutical company, which recently went public, has tripled.

Neumora focuses on central nervous system disorders. Its lead therapy is Navacaprant to treat MDD.